Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions Inc (NASDAQ: BLFS) maintains industry leadership through innovative biopreservation solutions for cell and gene therapies. This dedicated news hub provides comprehensive updates on corporate developments, regulatory milestones, and technological advancements essential for stakeholders in the life sciences sector.
Access official press releases covering quarterly earnings, strategic partnerships, and product innovations in cryopreservation media and cold chain management systems. Our curated collection serves investors and researchers requiring timely, accurate information about BLFS's role in advancing biologic manufacturing infrastructure.
The resource prioritizes updates on BioLife's core competencies: clinical-grade cell processing tools, smart shipper technologies, and quality assurance protocols critical for therapy commercialization. Content spans regulatory filings, manufacturing expansions, and intellectual property developments shaping the biostorage industry.
For consistent monitoring of BioLife's market position, bookmark this page or subscribe to Stock Titan's update alerts. All materials maintain strict editorial standards to support informed decision-making in the rapidly evolving cell therapy landscape.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products for cell and gene therapies and biopharma markets, has scheduled its third quarter 2024 financial results release for November 12, 2024, after market close. The company will host a conference call and webcast at 4:30pm ET to discuss financial results and provide a business update. Investors can access the webcast through BioLife's website, or join via phone using toll-free numbers. A replay will be available for 90 days on the company's investor relations page.
BioLife Solutions (Nasdaq: BLFS) announced its Q2 2024 financial results, highlighting an 11% sequential increase in Cell Processing revenue to $18 million. Total revenue for Q2 was $28.3 million, a 3% decrease year-over-year but a 6% sequential increase. The GAAP gross margin improved to 51%, while non-GAAP adjusted gross margin was 52%. The company experienced a GAAP net loss of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million, or 17%.
BioLife revised its full-year 2024 revenue guidance to between $99 million and $101 million and increased Cell Processing revenue guidance to $70 million to $71 million. The company also noted a $4.1 million write-off related to its iVexSol equity investment.
Additional business highlights include 12 new FDA Master File cross-references and the launch of the CellSeal CryoCase. The sale of the GCI freezer division was completed in April, and its financials have been excluded.
BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for cell and gene therapies and biopharma markets, has announced its second quarter 2024 financial results release date. The company will disclose its Q2 2024 results after market close on Thursday, August 8, 2024. Following the release, BioLife Solutions will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day.
During the call, management will provide an overview of the company's financial performance and offer a general business update. Investors and interested parties can access the webcast through the Investor Relations page on BioLife Solutions' website. For those preferring audio-only participation, a toll-free dial-in option is available. A replay of the webcast will be accessible approximately two hours after the call and will remain archived on the company's investor website for 90 days.
BioLife Solutions (NASDAQ: BLFS) introduced the CryoCase, a new addition to its CellSeal product line at the ISCT Conference in Vancouver. The CryoCase is designed for cell and gene therapy (CGT) primary packaging, aiming to replace cryopreservation bags with a fracture-resistant, rigid construction. It supports both manual and automated, closed-system use.
Available for demonstration at the ISCT event and expected to release to CGT developers in August, the CryoCase offers volume versatility, structural rigidity, and fill/retrieval port designs. It complies with USP 790 and USP 1790 standards and has shown high resistance to leaks and fractures during drop tests.
Early user tests indicated CryoCase may reduce particulates in single-use disposable manufacturing, potentially improving cell viability and recovery. Compatible with BioLife's Signata CT-5 system, CryoCase is expected to lower risks and costs in CGT manufacturing.
BioLife Solutions, Inc. (Nasdaq: BLFS) reported first quarter 2024 financial results with cell processing revenue up 10%, GAAP gross margin at 38%, net loss of $10.2 million, and adjusted EBITDA of $3.6 million. They affirmed revenue guidance for 2024, emphasizing realignment and divestiture of non-core assets to improve financials. Key financial metrics show revenue of $31.7 million, gross margin of 38%, and a net loss of $10.2 million. The company anticipates revenue growth in cell processing and biostorage services platforms.
BioLife Solutions, Inc. (NASDAQ: BLFS) will report its first quarter 2024 financial results on May 9, 2024. The company, a leading supplier of bioproduction tools and services for cell and gene therapies, will host a conference call and webcast to discuss the results and provide a business update. Investors can access the webcast and call details on the BioLife Solutions website.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
